Overview
Cystic fibrosis (CF) is a chronic, progressive disease that affects approximately 70,000 people worldwide. It is one of the most common life-threatening genetic disorders among Caucasians, with a median survival age of 47-52 years in the United States. CF is caused by mutations in the CFTR (cystic fibrosis transmembrane conductance regulator) gene, which codes for a protein essential for the transport of chloride and water in and out of cells. This genetic defect disrupts the normal functioning of the respiratory, digestive, and reproductive systems.
The symptoms of CF vary widely among individuals, but the most common manifestations include chronic lung infections, respiratory failure, pancreatic insufficiency, and malnutrition. In people with CF, the thick, sticky mucus that accumulates in the lungs creates a fertile ground for bacterial growth, leading to recurrent lung infections and inflammation. This chronic inflammation causes irreparable damage to the lung tissue, resulting in progressive respiratory decline.
History/Background
The first reported case of cystic fibrosis dates back to 1938, when Dr. William E. Ladd described a child with "fibrocystic disease of the pancreas." However, it wasn't until the 1960s that the genetic basis of the disease was identified, and subsequently, the CFTR gene was cloned in 1989. The discovery of the CFTR gene enabled the development of genetic testing for the disease, which has transformed the diagnosis and management of CF.
Key Information
Key facts about cystic fibrosis include:
* Prevalence: Approximately 1 in 3,300 Caucasian births are affected by CF.
* Genetic inheritance: CF is inherited in an autosomal recessive pattern, meaning that both parents must be carriers of the mutated gene to pass it on to their child.
* Symptoms: CF symptoms can include chronic lung infections, respiratory failure, pancreatic insufficiency, and malnutrition.
* Treatment: Treatment for CF typically involves a combination of medications, including bronchodilators, antibiotics, pancreatic enzyme supplements, and mucolytics.
* Life expectancy: Advances in treatment have significantly improved life expectancy for people with CF, with a median survival age of 47-52 years in the United States.
Significance
Cystic fibrosis has significant social, emotional, and economic implications for individuals, families, and society as a whole. The disease requires ongoing medical care, frequent hospitalizations, and significant lifestyle adjustments, which can be emotionally draining for patients and their families. However, advances in treatment and care have improved the quality of life for people with CF, enabling them to participate fully in education, employment, and other activities.
